Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02170090 |
|
Recruitment Status :
Active, not recruiting
First Posted : June 23, 2014
Last Update Posted : January 25, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cholangiocarcinoma Gall Bladder Carcinoma | Drug: Gemcitabine Drug: Cisplatin Drug: Capecitabine | Phase 3 |
The ACTICCA-1 investigator initiated trial is funded by the Deutsche Krebshilfe (grant number 70110215, 70112047). With respect to data obtained in the ABC-02 trial, the combination of cisplatin and gemcitabine for 24 weeks as investigational treatment was selected. Based on adjuvant trials in pancreatic cancer (e.g. ESPAC IV) with a comparable postoperative recovery time, inclusion of patients within a maximum interval of 16 weeks between surgery and start of CTx was chosen. Gemcitabine and cisplatin has a relevantly higher cumulative dose of gemcitabine 18 vs. 12 applications and may thus be of increased efficacy compared to the gemcitabine/oxaliplatin regimen applied in the PRODIGE 12 trial.
Based on the data of the BILCAP trial showing an improvement in median overall survival for capecitabine compared to observation alone presented at the annual meeting of the American Society of Clinical Oncology on June 4th 2017 in Chicago by the British BILCAP trial group, capecitabine has evolved as the new standard of care after curative intent resection of biliary tract cancer.
Based on these data the comparative efficacy of gemcitabine/cisplatin and capecitabine had to be established.
Therefore, the ACTICCA trial was amended to compare gemcitabine and cisplatin to the newly established standard regimen in the adjuvant setting capecitabine, aiming for superiority of the combination regimen vs. the oral monotherapy This was based on the BILCAP protocol, applying the similar dosing, assessments and dose modifications as in BILCAP, including dose calculation and patient diary.
As data of recent trials like the French PRODIGE 12/ACCORD 18 trial have clearly shown that in terms of efficacy of an adjuvant chemotherapy there is no difference between cholangiocarcinoma and gall bladder carcinoma, these two subtypes are pooled and location was added as an stratification factor.
Randomization will be 1:1 with adjuvant CTx for 24 weeks and imaging every 12 weeks in the experimental arm and standard of care (capecitabine) and observation in the control arm.
The primary endpoint is DFS and secondary endpoints include recurrence free survival, OS, safety and tolerability of adjuvant CTx, quality of life, and patterns of disease recurrence.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 789 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) |
| Study Start Date : | April 2014 |
| Estimated Primary Completion Date : | April 2023 |
| Estimated Study Completion Date : | April 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Gemcitabine plus Cisplatin
Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles) and Observation |
Drug: Gemcitabine
Gemcitabine 1000mg/m2 Drug: Cisplatin Cisplatin 25mg/m2 |
|
Active Comparator: Capecitabine
Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles) and Observation |
Drug: Capecitabine
Capecitabine 1250mg/m2 |
- Disease free survival (DFS) [ Time Frame: Disease free survival rate at 24 months (DFSR@24) ]DFS
- Disease free survival rate at 24 months (DFSR@24) [ Time Frame: 24 months ]DSFR
- Recurrence free survival [ Time Frame: 24 months ]RFS
- Overall survival [ Time Frame: 84 months ]OS
- Safety and tolerability (assessed by the rate of patients with adverse events according to NCI CTC AE v4.03) [ Time Frame: 24 months ]
- Quality of life [ Time Frame: 48 months ]QOL
- Function of biliodigestive anastomosis (in terms of surgical revision, requirement for PTCD) [ Time Frame: 48 months ]
- Rate and severity of biliary tract infections [ Time Frame: 48 months ]
- Patterns of disease recurrence [ Time Frame: 48 months ]
- locoregional control (assessed by the rate of patients with hepatic or locoregional recurrence) [ Time Frame: 48 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
All enrolled patients will postoperatively be assessed for eligibility for the treatment phase. Additionally patients not previously enrolled into the trial for whatever reason (e.g. incidental finding during surgery) will be evaluated for eligibility.
- Histologically confirmed adenocarcinoma of biliary tract (intrahepatic, hilar or extrahepatic cholangiocarcinoma or muscle invasive gallbladder carcinoma) after radical surgical therapy with macroscopically complete resection (mixed tumor entities (HCC/CCA) are excluded)
- Macroscopically complete resection (R0/1) within 6 (-16) weeks before scheduled start of chemotherapy
- ECOG 0-1
- Age ≥18 years
- Adequate hematologic function
- Adequate liver function
- Adequate renal function
- No active uncontrolled infection, except chronic viral hepatitis under antiviral therapy
- No concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to randomization
- Negative serum pregnancy test within 7 days of starting study treatment in pre-menopausal women and women <1 year after the onset of menopause (Note: a negative test has to be reconfirmed by a urine test, should the 7-day window be exceeded)
Criteria for initial study enrolment
- Written informed consent
- No prior chemotherapy for cholangiocarcinoma
- No previous malignancy within 3 years or concomitant malignancy, except: non-melanomatous skin cancer or adequately treated in situ cervical cancer
- No severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction in the last 3 months, significant arrhythmia)
- Absence of psychiatric disorder precluding understanding of information of trial related topics and giving informed consent
- No serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial
- Fertile women (< 1 year after last menstruation) and procreative men willing and able to use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile)
- No pregnancy or lactation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02170090
Show 67 study locations
| Principal Investigator: | Henning Wege | Universitätsklinikum Hamburg-Eppendorf |
| Responsible Party: | Universitätsklinikum Hamburg-Eppendorf |
| ClinicalTrials.gov Identifier: | NCT02170090 |
| Other Study ID Numbers: |
ACTICCA-1 2012-005078-70 ( EudraCT Number ) ACTRN12615001283561 ( Registry Identifier: ANZCTR (clinical trial registry) ) |
| First Posted: | June 23, 2014 Key Record Dates |
| Last Update Posted: | January 25, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
|
adjuvant chemotherapy cholangiocarcinoma muscle invasive gall bladder carcinoma |
translational research multidisciplinary AIO, DGAV, DGVS |
|
Carcinoma Cholangiocarcinoma Urinary Bladder Neoplasms Gallbladder Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Urinary Bladder Diseases Urologic Diseases Biliary Tract Neoplasms Digestive System Neoplasms |
Biliary Tract Diseases Digestive System Diseases Gallbladder Diseases Gemcitabine Capecitabine Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |